Man I couldn't disagree with you more PDude. This mgmt team has been a disaster and lost 95% of the value with a damn golden goose drug. I'll take new blood and a proven track record, as it's about time someone kicked ass.
Pharmacydude, All of us investors want to see shareholder value maximized and the uptake of Vascepa optimized. My view remains that only a BP owning AMRN can accomplish this. KM was hired for his expertise on getting approvals and reimbursements in Europe. Germany was certainly a major disappointment. If AMRN had been owned by a BP such as Bayer (with deep connections to Germany) I wonder if the negotiations would have had a different outcome. AMRN has always lacked the "gravitas" of a BP. Imagine if Pfizer decided that Vascepa would be a viable treatment for COVID induced CVD. My guess is that if COVID induced CVD were deemed to be a serious enough problem they could find a way to get governments to pay for it. My impression is that KM has no interest in selling the company. I think Denner would actively solicit the best possible deal for all concerned.
Pdude, the problem I have is that I believe AMRN management would use any positive stock price to dilute to aquire a pipeline. Isn't the guy they just added to the board today brought on for that purpose? He certainly wasn't added to sell the company.